First-trimester screening for preeclampsia

Česká verzia

Authors: L. Roubalová ^1,2 ; J. Vojtěch ³; J. Feyereisl ³; L. Krofta ³; A. Skřivánek ⁴; I. Marková ⁴; P. Lošan ⁵; R. Pilka ²; M. Lubušký ²
Authors place of work: Oddělení klinické biochemie Fakultní nemocnice, Olomouc ¹; Porodnicko-gynekologická klinika, Lékařská fakulta Univerzity Palackého a Fakultní nemocnice, Olomouc ²; Ústav pro péči o matku a dítě a 3. lékařská fakulta Univerzity Karlovy, Praha ³; G-CENTRUM Olomouc, Olomouc ⁴; Genetika Plzeň, Plzeň ⁵
Published in the journal: Ceska Gynekol 2019; 84(5): 361-370
Category: Přehledový článek

Summary

Design: Review article.

Setting: Department of Clinical Biochemistry, University Hospital Olomouc; Department of Obstetrics and Gynecology, Palacky University Olomouc, Faculty of Medicine and Dentistry, University Hospital Olomouc; The Institute for the Care of Mother and Child and 3rd Faculty of Medicine Charles University, Prague; G-CENTRUM Olomouc, Olomouc; Genetika Plzeň, Pilsen.

Methods, results: Preeclampsia (PE) is a multisystem disorder complicating pregnancy. It is the leading cause of maternal and perinatal mortality and morbidity worldwide. Recent studies have shown that high-risk pregnant women may benefit from low-dose acetylsalicylic acid early therapy in prevention of the development of severe forms of the disease. The risk group of pregnant women should be identified in 11–13 gestational week for effective prevention. The only procedure validated in many studies for performing PE screening with sufficient diagnostic accuracy in the first trimester of pregnancy is given by The Fetal Medicine Foundation (FMF) and has been adopted and published in a new recommendation by The International Federation of Gynecology and Obstetrics (FIGO).

Conclusion: This article summarizes the recent findings and recommendation for performing screening of preeclampsia in 1st trimester of pregnancy and how to prevent the development of severe forms of PE by low-dose acetylsalicylic acid therapy.

Keywords:

cervical length measurement – preeclampsia – maternal risk factors – mean arterial pressure – Uterine artery Pulsatility Index – Placental Growth Factor – acetylsalicylic acid – parameters

Zdroje

1. A transcript of Professor Kypros Nicolaides‘s webcast, broadcast on April 24th 2018, First Trimester Prediction and Prevention of Pre-term Pre-eclampsia.

2. ACOG Practice Bulletin No. 202: Gestational Hypertension and Preeclampsia. Obstet Gynecol, 2019, 133(1), p. e1–e25.

3. Brosens, I., Pijnenborg, R., Vercruysse, L., Romero, R. The „Great Obstetrical Syndromes“ are associated with disorders of deep placentation. Am J Obstet Gynecol, 2011, 204(3), p. 193–201.

4. Brown, MA., Magee, LA., Kenny, LC., et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis & management recommendations for international practice. Pregnancy Hypertens, 2018, 13, p. 291–310.

5. Bujold, E., Roberge, S., Nicolaides, KH. Low-dose aspirin for prevention of adverse outcomes related to abnormal placentation. Prenat Diagn, 2014, 34, p. 642–648.

6. Carbillon, L., Challier, JC., Alouini, S., et al. Uteroplacental circulation development: Doppler assessment and clinical importance. Placenta, 2001, 22, p. 795–799.

7. Carbillon, L., Perrot, N., Uzan, M., Uzan, S. Doppler ultrasonography and implantation: A critical review. Fetal Diagn Ther, 2001, 16, p. 327–332.

8. Doporučený postup ČGPS ČLS JEP č.6/2019 sb. Management hypertenzních onemocnění v těhotenství, http://www.gynultrazvuk.cz/data/clanky/6/dokumenty/2019–06-management-hypertenznich-onemocneni-v-tehotenstvi-dp-cgps-cls-jep-revize.pdf

9. Doporučený postup ČGPS ČLS JEP č.1/2019 sb.: Zásady dispenzární péče v těhotenství, http://www.gynultrazvuk.cz/data/clanky/6/dokumenty/2019-01-zasady-dispenzarni-pece-v-tehotenstvi-dp-cgps-cls-jep-revize.pdf

10. Dugoff, L., Hobbins, JC., Malone, FD., et al. First-trimester maternal serum PAPP-A and free-beta subunit human chorionic gonadotropin concentrations and nuchal translucency are associated with obstetric complications: a population-based screening study (the FASTER Trial). Am J Obstet Gynecol, 2004, 191, p. 1446–1451.

11. Duhig, K., Vandermolen, B., Shennan, A. Recent advances in the diagnosis and management of pre-eclampsia. F1000Res. 2018, 7, p. 242.

12. Excellence. NIfHaC. CG107 NICE Guideline: Hypertension in Pregnancy, 2012.

13. Figueras, F., Gratacos, E., Rial, M., et al. Revealed versus concealed criteria for placental insufficiency in an unselected obstetric population in late pregnancy (RATIO37): randomized controlled trial study protocol. BMJ Open, 2017, 15.

14. Hofmeyr, GJ., Lawrie, TA., Atallah, AN., et al. Calcium supplementation during pregnancy for preventing hypertensive disorders and related problems. Cochrane Database Syst Rev, 2014, 6: CD001059.

15. Högberg, U. The World Health Report 2005: „make every mother and child count“ – including Africans. Scand J Public Health, 2005, 33(6), p. 409–411.

16. Chan, SL., et al. Analytical validation of soluble fms-like tyrosine and placental growth factor assays on B·R·A·H·M·S KRYPTOR Compact Plus automated immunoassay platform. Pregnancy Hypertens, 2018, 11, p. 66–70.

17. Ľubušký, M., Machač, Š. Prenatální dopplerometrie. Lék Listy, 2003, 41, s. 11–13.

18. Magee, LA., Pels, A., Helewa, M., Rey, E., von Dadelszen, P. Canadian Hypertensive Disorders of Pregnancy (HDP) Working Group. Diagnosis, evaluation, and management of the hypertensive disorders of pregnancy. Pregnancy Hypertens, 2014, 4(2), p. 105–145.

19. Melchiorre, K., Wormald, B., Leslie, K., et al. First-trimester uterine artery doppler indices interm and preterm pre-eclampsia. Ultrasound Obstet Gynecol, 2008, 32, p. 133–137.

20. National Heart Foundation of Australia. Hypertension Management Guide for Doctors. 2004. [website] www.heartfoundation.org.au. Accessed April 1, 2006.

21. O‘Gorman, N., et al. Competing risks model in screening for preeclampsia by maternal factors and biomarkers at 11–13 weeks gestation. Am J Obstet Gynecol, 2016, 214(1), p. 103.e1–103.e12

22. Olofsson, P., Laurini, RN., Marsal, K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol, 1993, 49, p. 161–168.

23. Phibbs, CS., Schmitt, SK., Cooper, M., et al. Birth hospitalization costs and days of care for mothers and neonates in California, 2009–2011. J Pediatr. 2019, 204, p. 118–125.e14.

24. Poon, LC., et al. The International Federation of Gynecology and Obstetrics (FIGO) initiative on pre-eclampsia: A pragmatic guide for first-trimester screening and prevention. Int J Gynaecol Obstet, 2019, 145, Suppl. 1, p. 1–33.

25. Poon, LC., Kametas, NA., Pandeva, I., et al. Mean arterial pressure at 11(+0) to 13(+6) weeks in the prediction of preeclampsia. Hypertension, 2008, 51, p. 1027–1033.

26. Poon, LC., Kametas, NA., Valencia, C., et al. Hypertensive disorders in pregnancy: Screening by systolic diastolic and mean arterial pressure at 11–13 weeks. Hypertens Pregnancy, 2011, 30, p. 93–107.

27. Pourat, N., Martinez, AE., Jones, JM., et al. Costs of gestational hypertensive disorders in California: hypertension, preeclampsia, and eclampsia. Los Angeles, CA: UCLA Center for Health Policy Research, 2013.

28. Raymond, D., Peterson, E. A critical review of early-onset and late-onset preeclampsia. Obstet Gynecol Surv, 2011, 66, p. 497–506.

29. Rolnik, DL., et al. Aspirin versus placebo in pregnancies at high risk for preterm preeclampsia. N Engl J Med, 2017, 377 (7), p. 613–622.

30. Salahuddin, S., et al. KRYPTOR-automated angiogenic factor assays and risk of preeclampsia-related adverse outcomes. Hypertens Pregnancy, 2016, 35(3), p. 330–345.

31. Smith, GC., Stenhouse, EJ., Crossley, JA., et al. Early pregnancy levels of pregnancy-associated plasma protein a and the risk of intrauterine growth restriction, premature birth, preeclampsia, and stillbirth. J Clin Endocrinol Metab, 2002, 87, p. 1762–1767.

32. Sotiriadis, A., Hernandez-Andrade, E., da Silva Costa, F., et al. ISUOG Practice Guidelines: Role of ultrasound in screening for and follow-up of pre-eclampsia. Ultrasound Obstet Gynecol, 2019, 53, p. 7–22.

33. Společný doporučený postup ČSKB ČLS JEP a SLG ČLS JEP: Doporučení o laboratorním screeningu vrozených vývojových vad v prvním a druhém trimestru těhotenství. http://www.cskb.cz/res/file/doporuceni/2018/doporuceni-7-5-2018-vidiSLG.pdf

34. Stepan, H., et al. Elecsys® and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable? Clin Chem Lab Med, 2019, 57(9), p. 1339–1348.

35. Tan, MY., et al. Comparison of diagnostic accuracy of early screening for pre-eclampsia by NICE guidelines and a method combining maternal factors and biomarkers: results of SPREE. Ultrasound Obstet Gynecol, 2018, 51(6), p. 743–750.

36. Tan, MY., et al. Screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks‘ gestation. Ultrasound Obstet Gynecol, 2018, 52(2), p. 186–195.

37. The Fetal Medicine Foundation. http://www.fetalmedicine.com

38. Thilaganathan, B. Author‘s reply re: Pre-eclampsia is primarily a placental disorder: AGAINST: Pre-eclampsia: the heart matters. BJOG, 2018, 125(4), p. 512–513.

39. Thilaganathan, B. Placental syndromes: getting to the heart of the matter. Ultrasound Obstet Gynecol,. 2017, 49(1), p. 7–9.

40. Valensise, H., Vasapollo, B., Gagliardi, G., Novelli, GP. Early and late preeclampsia: two different maternal hemodynamic states in the latent phase of the disease. Hypertension, 2008, 52(5), p. 873–880.

41. van Helden, J., Weiskirchen, R. Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia. Clin Biochem, 2015, 48(16–17).

42. Vane, JR., Botting, RM. The mechanism of action of aspirin. Thromb Res, 2003, 110(5–6), p. 255–258.

43. Velauthar, L., Plana, MN., Kalidindi, M., et al. First-trimester uterine artery Doppler and adverse pregnancy outcome: A meta-analysis involving 55,974 women. Ultrasound Obstet Gynecol, 2014, 43, p. 500–507.

44. Verlohren, S. Author‘s reply re: Pre-eclampsia is primarily a placental disorder: FOR: Pre-eclampsia is primarily a placental disorder. BJOG, 2018, 125(4), p. 513–514.

45. Vlk, R., Procházka, M., Měchurová, A., et al. Preeklampsie – od patofyziologie ke klinické praxi, 1. vyd. Praha: Maxdorf, 2015.

46. Von Dadelszen, P., Magee, LA., Roberts, JM. Subclassification of preeclampsia. Hypertens Pregnancy, 2003, 22, p. 143–148.

47. Wright, D., Rolnik, DL., Syngelaki, A., et al. Aspirin for Evidence-Based Preeclampsia Prevention trial: Effect of Aspirin on length of stay in the neonatal intensive care unit. Am J Obstet Gynecol, 2018, 218, p. 612. e1–612.e6.

48. Wright, D., Silva, M., Papadopoulos, S., et al. Serum pregnancy-associated plasma protein –A in the three trimesters of pregnancy: Effects of maternal characteristics and medical history. Ultrasound Obstet Gynecol, 2015, 46, p. 42–50.

49. Wright, D., Akolekar, R., Syngelaki, A., et al. A competing risks model in early screening for preeclampsia. Fetal Diagn Ther, 2012, 32(3), p. 171–178.